" class="no-js "lang="en-US"> Camber Pharma Launches Generic Kaletra - Medtech Alert
Saturday, June 10, 2023

Breaking News

Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Sir Richard Roberts Elected to National Academy of Sciences Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM) Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases
Camber Pharma Launches Generic Kaletra | Pharmtech Focus

June 9 2021

Camber Pharma Launches Generic Kaletra

Camber Pharmaceuticals is pleased to announce that it has launched Lopinavir and RitonavirTablets, which is the generic version of Kaletra®

Lopinavir and Ritonavir Tablets are used with other HIV medications to help control HIV infection.Lopinavir and Ritonavir Tablets are available from Camber in 100 mg/25 mg- 60 count and 200 mg/50 mg- 120 count bottles.

Camber Pharmaceuticals is a fully integrated international pharmaceutical company that maintains quality and integrity in all its products. Its parent company, Hetero Drugs of Hyderabad India, is one of the world’s leading API and finished dosage manufacturers. Camber’s commitment to the consumer is to bring the highest quality generic pharmaceuticals to the market to improve quality of life through cost-effective medications.

Companies In This Post

Camber Pharmaceuticals | Pharmtech Focus

Camber Pharmaceuticals
  1. Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration

    Gene Therapy

     Read more
  2. Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

    Diseases

     Read more
  3. Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas

    Clinical Trials

     Read more
  4. Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases

    News

     Read more
  5. Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430

    Drug Development

     Read more
More On